AIML Announces SEDAR Filing
AI/ML Innovations (OTCQB:AIMLF) has filed an amended and restated management's discussion and analysis (MD&A) for the periods ending January 31, 2025, following a review by the British Columbia Securities Commission. The amended filing addresses several disclosure deficiencies.
The enhanced disclosure includes details about new strategic initiatives, R&D activities, operational results, and the acquisition of Quantum Sciences Ltd. Additional information covers related party payments, an exit agreement with Tech2Heal, and other minor updates. The complete Amended MD&A is accessible on SEDAR+.
AI/ML Innovations (OTCQB:AIMLF) ha presentato una versione emendata e riformulata della discussione e analisi della direzione (MD&A) relativa ai periodi terminati il 31 gennaio 2025, a seguito di una revisione da parte della British Columbia Securities Commission. Il deposito corretto risolve diverse carenze informative.
Le informazioni ampliate includono dettagli sulle nuove iniziative strategiche, le attivit脿 di R&D, i risultati operativi e l'acquisizione di Quantum Sciences Ltd. Vengono inoltre fornite informazioni su pagamenti a parti correlate, un accordo di uscita con Tech2Heal e altri aggiornamenti minori. L'MD&A emendata completa 猫 disponibile su SEDAR+.
AI/ML Innovations (OTCQB:AIMLF) present贸 una versi贸n enmendada y reformulada de la discusi贸n y an谩lisis de la administraci贸n (MD&A) correspondiente a los periodos terminados el 31 de enero de 2025, tras una revisi贸n por la British Columbia Securities Commission. La presentaci贸n enmendada corrige diversas deficiencias de divulgaci贸n.
La divulgaci贸n ampliada incluye detalles sobre las nuevas iniciativas estrat茅gicas, actividades de I+D, resultados operativos y la adquisici贸n de Quantum Sciences Ltd. Tambi茅n se a帽aden datos sobre pagos a partes vinculadas, un acuerdo de salida con Tech2Heal y otras actualizaciones menores. El MD&A enmendado completo est谩 disponible en SEDAR+.
AI/ML Innovations (OTCQB:AIMLF)電� 敫岆Μ韹办嫓旎熂牍勳晞 歃濌秾鞙勳洂須岇潣 瓴�韱犾棎 霐半澕 2025雲� 1鞗� 31鞚茧 膦呺霅橂姅 旮瓣皠鞐� 雽�頃� 瓴届榿歆� 雲检潣 氚� 攵勳劃(MD&A)鞚� 靾橃爼路鞛瀾靹表晿鞐� 鞝滌稖頄堨姷雼堧嫟. 靾橃爼 鞝滌稖鞚� 鞐煬 瓿奠嫓 雸勲澖 靷暛鞚� 頃挫唽頃╇媹雼�.
臧曧檾霅� 瓿奠嫓鞐愲姅 靸堧鞖� 鞝勲灥鞝� 鞚措媹靺旐嫲敫�, 鞐瓣惮臧滊皽 頇滊彊, 鞓侅梾 鞁れ爜 氚� Quantum Sciences Ltd 鞚胳垬鞐� 甏�頃� 靹鸽秬 鞝曤炒臧� 韽暔霅╇媹雼�. 霕愴暅 甏�霠� 雼轨偓鞛� 歆�旮�, Tech2Heal瓿检潣 膦呺 頃╈潣 氚� 旮绊儉 靻岅窚氇� 鞐呺嵃鞚错姼鞐� 甏�頃� 鞝曤炒霃� 鞝滉车霅╇媹雼�. 鞝勳泊 靾橃爼 MD&A電� SEDAR+鞐愳劀 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
AI/ML Innovations (OTCQB:AIMLF) a d茅pos茅 une version modifi茅e et reformul茅e de la discussion et analyse de la direction (MD&A) pour les p茅riodes cl么tur茅es le 31 janvier 2025, 脿 la suite d'un examen par la British Columbia Securities Commission. le d茅p么t amend茅 corrige plusieurs lacunes de divulgation.
Les informations enrichies comprennent des d茅tails sur les nouvelles initiatives strat茅giques, les activit茅s de R&D, les r茅sultats op茅rationnels et l'acquisition de Quantum Sciences Ltd. Sont 茅galement fournis des renseignements sur les paiements 脿 des parties li茅es, un accord de sortie avec Tech2Heal et d'autres mises 脿 jour mineures. La MD&A amend茅e compl猫te est accessible sur SEDAR+.
AI/ML Innovations (OTCQB:AIMLF) hat nach einer 脺berpr眉fung durch die British Columbia Securities Commission eine berichtigte und neu gefasste Management-Diskussion und -Analyse (MD&A) f眉r die zum 31. Januar 2025 endenden Perioden eingereicht. Die berichtigte Einreichung behebt mehrere Offenlegungsm盲ngel.
Die erweiterte Offenlegung enth盲lt Einzelheiten zu neuen strategischen Initiativen, F&E-Aktivit盲ten, Betriebsergebnissen und der 脺bernahme von Quantum Sciences Ltd. Zus盲tzliche Angaben betreffen Zahlungen an nahestehende Parteien, eine Austrittsvereinbarung mit Tech2Heal und weitere kleinere Aktualisierungen. Die vollst盲ndige berichtigte MD&A ist auf SEDAR+ einsehbar.
- Proactive compliance with regulatory requirements through enhanced disclosure
- Strategic acquisition of Quantum Sciences Ltd and associated intellectual property
- Required amendments to MD&A due to disclosure deficiencies identified by regulators
- Exit agreement with Tech2Heal indicating discontinued business relationship
VANCOUVER, BC / / August 21, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is issuing the following press release to clarify its disclosure as a result of a review by the British Columbia Securities Commission.
The Company announces today that it has filed an amended and restated management's discussion and analysis for the three and nine month periods ended January 31, 2025 (the "Amended MD&A") in order to rectify certain disclosure deficiencies, including:
to provide enhanced disclosure relating to (i) new strategic initiatives and R&D activities of the Company; (ii) the results of operations of the Company for the three and nine month periods ended January 31, 2025; and (iii) the acquisitions by the Company of Quantum Sciences Ltd. and certain other intangible assets and associated intellectual property during the period;
to incorporate additional details regarding payments made to related parties during the period;
to include a discussion of the exit agreement with Tech2Heal; and
to incorporate other minor housekeeping changes.
The Amended MD&A is available on SEDAR+ at .
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at .
Contact:
Blake Fallis
(778) 405-0882
[email protected]
About AIML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE: AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
On behalf of the Board of Directors:
Paul Duffy, Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Such statements remain subject to various risks, including risks relating to the proposed future operations of the Company, availability of funding, industry developments and competition. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company disclaims any obligation to update such forward looking statements other than as required by law.
SOURCE: AI/ML Innovations, Inc.
View the original on ACCESS Newswire
FAQ
What changes did AIML (AIMLF) make to its MD&A filing in August 2025?
Why did AIML (AIMLF) need to amend its January 2025 MD&A?
What acquisitions did AIML (AIMLF) disclose in its amended MD&A?
What is the significance of AIML's exit agreement with Tech2Heal?
